To test ADTGP in a real-world dataset, we focus on how treatment with ivosidenib, a mutant IDH1 inhibitor, can induce the differentiation of IDH-mutated AML cells in vivo. This evidence concerns the gene IDH1 and acute myeloid leukemia.